Rishad Shiraz

Rishad Shiraz

Auto-generated profile, based on publicly available information

Rishad Shiraz

Emerging Viral Pathogens Laboratory Infosys Wing Centre for Infectious Disease Research Indian Institute of Science Bengaluru India

Research Focus & Metrics

Academic Career Length

1Year (2026-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
22 October 2026 in Advanced Science
Verified
Journal Article
Open access
PDF file
OKOyahida Khatun
Oyahida Khatun
RNRohan Narayan
Rohan Narayan
SNSanthosh Kambaiah Nagaraj
Santhosh Kambaiah Nagaraj
RSRishad Shiraz
Rishad Shiraz
AKAbinaya Kaliappan
Abinaya Kaliappan
Shashank TripathiShashank Tripathi
Shashank Tripathi
Auranofin, an FDA‐approved oral anti‐rheumatic drug, was previously shown by our group to restrict Severe Acute Respiratory Syndrome Coronavirus‐2 (SARS‐CoV‐2) replication and pathology in preclinical models. Here, we systematically characterized its mechanism of action (MOA) through biochemical drug‐protein interactions, cell‐based mechanistic assays, and preclinical efficacy studies. Auranofin directly binds and inhibits SARS‐CoV‐2 MPro while simultaneously targeting multiple stages of the viral life cycle, disrupting endosomal trafficking, suppressing Spike S1/S2 proteolytic processing, impairing syncytia formation, and attenuating NF‐κB‐driven proinflammatory signaling. In cell culture, Auranofin demonstrated robust synergy with Remdesivir but competed with the MPro inhibitor Nirmatrelvir, informing rational combination design. In mice infected with the SARS‐CoV‐2 Delta variant, the oral combination of Auranofin and the Remdesivir prodrug GS‐621763 outperformed monotherapy, markedly reducing viral replication, inflammatory cytokine responses, and lung pathology, and improving clinical outcomes. These findings establish a multi‐target antiviral MOA of Auranofin and provide a mechanistic rationale for an all‐oral antiviral combination regimen against COVID‐19.